Teva reveals critical Ajovy data
Therapy has been developed to reduce the frequency, duration and severity of migraine attacks
Read More
Tag: Ajovy
UK launch for Ajovy injector pen
Teva’s new device allows migraine sufferers to self-administer the drug
Read More
NICE publishes final guidance backing Teva’s Ajovy for migraine
One in seven UK adults is affected by migraine
Read More
Ajovy bags NICE approval
The anti-CGRP preventive therapy is the first of-its-kind to be recommended by NICE.
Read More
Zytiga, Ajovy among latest SMC decisions
The group also accepted drugs for primary progressive multiple sclerosis and a rare form of lymphoma.
Read More
IONTAS, Teva announce new antibody optimisation agreement
Teva recently halted its Ajovy clinical development.
Read More
Teva abandons Ajovy trial for cluster headaches
A Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.
Read More
European approval for Teva’s migraine drug Ajovy
The drug is a pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month.
Read More
Teva’s anti-CGRP drug Ajovy cleared for migraine prevention
US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
